Tag: Ticagrelor

1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for patients with...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for...
1. There does not appear to be any difference in outcome between pre- and post-treatment administration of P2Y12 inhibitors among patients experiencing a non-ST elevation acute coronary syndrome with planned invasive intervention. 2. Prasugrel and ticagrelor showed similar outcomes when administered post-treatment. Evidence Rating Level: 1 (Excellent) Though it is well established...
1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...
1. Ticagrelor and aspirin taken after a mild-to-moderate acute non-cardioembolic stroke or high-risk transient ischemic attack led to a lower rate of subsequent stroke within 30 days. 2. The incidence of overall disability at 30 days did not differ between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Following an acute ischemic...
1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...
1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...
1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did not differ between men and women. Evidence Rating Level: 1 (Excellent) Percutaneous coronary intervention (PCI) is a highly effective treatment in coronary...
Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did not differ between men and women. Evidence Rating Level: 1 (Excellent) Percutaneous coronary intervention (PCI) is a highly effective treatment in coronary...